ArticleFrontiers in immunology2025
Exploring the role of NOD2 variants in pediatric undifferentiated recurrent fever: a clinical and functional perspective.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Syndrome of Undifferentiated Recurrent Fever (SURF) is an autoinflammatory disorder with onset in childhood, marked by recurrent episodes of fever without an established molecular diagnosis. Although NOD2 gene variants that are generally considered non-pathogenic are often identified in these patients, their contribution to disease development is still not well understood. Methods: This study aimed to assess the clinical characteristics, long-term progression, and functional implications of NOD2 variants in a group of twelve children diagnosed with SURF, along with two Blau syndrome cases and two healthy controls. Clinical information was gathered at presentation and during follow-up. Peripheral blood mononuclear cells were examined for cytokine secretion and NF-kB pathway activation, both at baseline and following muramyl dipeptide stimulation, using multiplex cytokine analysis, Western blot, and ELISA. Results: The median follow-up period was 3.75 years, with most children developing symptoms before 10 years of age. Abdominal pain and limb pain were the most frequent complaints. All patients were treated with colchicine, and selected cases required corticosteroids or disease-modifying antirheumatic drugs. Elevated levels of proinflammatory cytokines, including IL-2, TNF-a, IL- 6, and IL-8, were observed in SURF patients. Our functional studies suggested that variants like R702W, G908R, P268S/V955I, and R702W/P268S might have triggered stronger inflammatory responses, whereas L682F, L1007fs, and R587C might have been linked to diminished cytokine production and lower NF-kB activity. Certain variants, such as A1000T and P268S, appeared to show baseline NF-kB activation with moderate inflammatory activity. Discussion: Our findings emphasize the clinical and functional diversity of NOD2 variants in SURF and may point to a possible genotype-phenotype relationship that could aid in understanding disease pathways and refining diagnostic approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.